title: The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
authors: Princess Margaret Cancer Centre, Toronto, ON, Canada vikas.gupta@uhn.on.ca.
authors: Vikas
authors: V
authors: Gupta
authors: Guy's and St Thomas' NHS Foundation, London, UK.
authors: Claire
authors: C
authors: Harrison
authors: University of Pennsylvania, Philadelphia, PA, USA.
authors: Elizabeth O
authors: EO
authors: Hexner
authors: University Hospital of Leipzig, Germany.
authors: Haifa Kathrin
authors: HK
authors: Al-Ali
authors: St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
authors: Lynda
authors: L
authors: Foltz
authors: Incyte Corporation, Wilmington, DE, USA.
authors: Michael
authors: M
authors: Montgomery
authors: Incyte Corporation, Wilmington, DE, USA.
authors: William
authors: W
authors: Sun
authors: Novartis Pharma AG, Basel, Switzerland.
authors: Prashanth
authors: P
authors: Gopalakrishna
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Hagop
authors: H
authors: Kantarjian
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Srdan
authors: S
authors: Verstovsek
mesh_terms: D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality*; D005260:Female; D006801:Humans; D008297:Male; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
keywords: JAK inhibitor; anemia; myelofibrosis; overall survival; ruxolitinib